Physician profile
Bhavin C Patel
NPI 1619234416
$2,221.37
in general payments reported to CMS, 2019-2025
18 companies · $1,323 in 2025
The $1,323 reported for 2025 was more than what 84% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $242 · 2020: $188 · 2021: $28.97 · 2022: $111 · 2023: $84.58 · 2024: $244 · 2025: $1,323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,102 · Travel and Lodging: $550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,102.15 |
| Travel and Lodging | $550.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $1,115.98 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Otsuka America Pharmaceutical, INC. | $308.36 | 2019-2024 | Jynarque |
| Abbvie INC. | $193.58 | 2022-2025 | |
| Glaxosmithkline, LLC. | $87.38 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Baxter Healthcare | $84.58 | 2023 | Renal - Pd |
| Astrazeneca Pharmaceuticals LP | $84.57 | 2019-2024 | Lokelma |
| Lexicon Pharmaceuticals, INC. | $72.38 | 2024 | Inpefa |
| Vifor Pharma, INC. | $43.59 | 2019-2020 | |
| Hikma Pharmaceuticals USA | $34.12 | 2024 | Ryaltris |
| Novartis Pharmaceuticals Corporation | $33.77 | 2025 | |
| Stryker Corporation | $29.26 | 2025 | Inthrill Thrombectomy Catheter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.18 | 2024 | Jardiance |
| Aurinia Pharma U.S., INC. | $24.51 | 2025 | Lupkynis |
| Horizon Therapeutics Plc | $22.70 | 2020 | |
| Fresenius USA Marketing, INC. | $21.17 | 2025 | Crit-Line, 2008t Bluestar Hemodialysis Machine, Optiflux |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $13.88 | 2025 | Empaveli |
| Mallinckrodt Hospital Products INC. | $11.21 | 2020 | |
| Akebia Therapeutics INC | $11.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bhavin Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.